Heterozygous HTRA1-related cerebral small vessel disease

Last revised by Rohit Sharma on 13 Mar 2024

Heterozygous HTRA1-related cerebral small vessel disease, also known as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy type 2 (CADASIL2), is a very rare monogenic cerebral small vessel disease.

Heterozygous HTRA1-related cerebral small vessel disease is an HTRA1-related cerebral small vessel disease, and thus is closely related to, but distinct from, cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL).

Heterozygous HTRA1-related cerebral small vessel disease is likely very rare, although its true incidence and prevalence are not known. The condition tends to clinically manifest between the third and sixth decades of life 1-3.

The clinical presentation of heterozygous HTRA1-related cerebral small vessel disease may be asymptomatic, but when symptomatic, is similar to CARASIL, albeit milder 1,2.

Neurological clinical features in symptomatic patients 1-3:

Non-neurological clinical features in symptomatic patients 1,2:

Heterozygous HTRA1-related cerebral small vessel disease, as its name suggests, is caused by a monoallelic mutation in HTRA1, the same gene implicated in CARASIL 1-4. The mechanisms by which a mutation in a single allele causes cerebral small vessel disease is not fully elucidated, but is thought to be due to either haploinsufficiency or dominant-negative effects 1,2. In some instances, the monoallelic mutation may demonstrate an autosomal dominant pattern of inheritance through a pedigree, however, the penetrance is low 1-3.

MRI is the imaging modality of choice and demonstrates the following features 1-4:

No specific disease-modifying treatment is available and thus, management is supportive and symptomatic.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.